Skip to search formSkip to main contentSkip to account menu

ALX-0061

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Single-Domain Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Novartis' lung cancer ALK inhibitor approved
2014
2014
DBN employees charged with agricultural espionage
Regulators have backed Janssen’s first-in-class, anti-interleukin-6 (IL-6) Sylvant (siltuximab) for multicentric Castleman’s… 
2013
2013
FRI0021 Alx-0061, an anti-IL-6r nanobody® for therapeutic use in rheumatoid arthritis, demonstrates in vitro a differential biological activity profile as compared to tocilizumab
Background Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor, which… 
2012
2012
preclinical Development of Alx-0061, an Anti-il-6r Nanobody® for therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)